Company intelligence / Profile preview

Rubic One Health

Johannesburg, Gauteng, South Africarubiconehealth.co.za ↗

Ownership: Private
Development stage: Other

Overview

COVID-19 RBD booster vaccine (DYAI-100): Ongoing first-in-human Phase 1 trial. No serious adverse events reported after dosing; preliminary safety assessment expected June 2023. Other pipeline programs are in earlier development or pre-clinical stage.

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccineMonoclonal antibodyRecombinant proteinVirus-like particleFerritin nanoparticle
Industry: Biotech

Partnerships

Dyadic International (C1 platform license and technology transfer)Afreximaxbank (facility/project funding for vaccine manufacturing)University of the Witwatersrand (Wits) and Wits Health Consortium (R&D, clinical, operational support)

Beyond the preview

Go deeper on Rubic One Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rubic One Health.